|
| |
|
|
| |
|
|
2008 iBio
(May 18-22, 2008,Hangzhou,China)
|
|
|
|
|
|
|
|
|
|
|
|
|
CEMD-2008
(
Oct.22-28, 2008, Beijing & Xi'an, China )
|
|
|
WCV 2008
( Dec.1-5, 2008, Guangzhou, China) |
|
|
|
|
|
|
WCG 2008
(Dec. 5-7, 2008, Guangzhou, China)
|
|
|
|
|
|
| |
| Scientific Program |
|
|
|
|
08 IDDST Tentative Program
Time: October 18-22, 2008
Venue: Loong Palace Hotel, Beijing, China
|
| Pre-Conference Summit : |
| |
| Oct.17, 2008
13:30-17:30 |
| Workshop 1: How to File IND with China SFDA |
| Workshop 2: What Policy Privilege for Foreign Inventor to Develop Biopharmaceuticals in China |
| Workshop 3: Opportunities and Challenges upon Off-Patent Blockbusters |
|
| Oct.22, 2008
8:30-11:30 |
| Workshop 4: New Paradigm of Alliance /Collaborative Drug Discovery with Academia in China |
| Workshop 5: How to Meet FDA Requirement by Performing Effective Clinical Trials for INDs in China |
| Workshop 6: Botanical Drugs: Production, Analyses and FDA Regulations
Dr. J. Briggs, Director, National Center for Complementary and Alternative Medicine, NIH, USA
Objective: Outlining the scientific, clinical and regulatory steps involved in transformation of herbal medicines to safe and effective botanical drugs.

Topics:
1. Data collection on efficacy and safety, to show safe human use.
Documentation of clinical data based on traditional healers' practice, documentation of the quality (chemical and biological characterization) of the product used.
2. Good agricultural and collection practices, and Good manufacturing practices, to ensure batch to batch consistency. 3. Chemical characterization of complex mixture used in traditional medicine
4. Characterization by biological tests
5. Pharmacological studies.
6. Toxicological studies.
7. Clinical studies
8. Collaborations (as collection of plants and transport may be an issue and also some of the activity may be lost)
- Scientific and clinical collaborations
- environmental consideration.
9. Patent and marketing exclusivities
10. FDA ¨C preparation of application using ICH guidelines, preparation of eCTD. |
|
|
| |
| The Main Scientific Program will take place from 09:00-17:00 during October 18-22, 2008. 600+ Research and Industrial Presentations divided into six tracks with sixty-eight sessions in total. The ten sessions offered will run concurrently per half day.
Click following session number for detailed program:
| Morning of October 19 |
|
Plenary Lectures
-- From Novel Targets to Billion Dollar Molecules
Special Symposium Sponsored by ACS-Medichem Division
|
Morning of October 20 |
|
Track 2: How Advanced Medicinal Chemistry Help Your prototype molecules to Blockbusters
-Listen to Successful Case Story from Big Phmarmas and Enjoy the Voice of ACS Medichem

|
Morning of October 20 |
|
Track 3: Translational Cutting-Edge Technologies
-Speeding Discovery Process with Niches
For Detail Track Info: Click here, Session 26-35
|
Morning of October 20, Afternoon of October 21, Morning of October 22 |
|
Track 4: Therapeutics Development for Major and Rare Diseases
-Delivering Promises for Future Drugs
For Detail Track Info: Click here, Session 36-55
|
Morning of October 22 |
|
Track 5:: Nature Product Based Drug Discovery
-Mining 5000 Year Nature Pool
For Detail Track Info: Click here, Session 56-60
|
Morning of October 22 |
|
Track 6: Drug R & D Partnering in China
-Integrating Resources and Talents from the East To Slow Your Money Burning Rate Increase pipeline successful percentage
For Detail Track Info: Click here, Session 61-65
|
|
| |
| |
| Track 1: Drug Discovery Sciences |
¡øTOP |
| -Great Thoughts for Deciphering Human Disorders |
| |
Time |
Sessions |
Oct.18, 2008
Saturday
13:30-17:30
|
Session 1:
¡°-Omics¡±, Molecular Genetics to System Biology and Drug Discovery |
Session Chair: |
Dr. Christian Pasquali, Professor, Geneva Research Center, Merck Serono International S.A., Switzerland |
Co-Chair: |
Call for Co-Host |
| 13:30-13:55 |
Title: HPLC-Chip/MS: a New Powerful Analytical Technology
Dr. Rudolf Grimm, Market Development Manager, Agilent Technologies Inc., USA |
| 13:55-14:20 |
Title: TBD
Dr. Ira L. Goldknopf, Director of Proteomics, Power3 Medical Products, Inc., USA |
| 14:20-14:45 |
Title: Importance of Physical Prediction in Peptide/Protein Fractionation for the Cleanup of Bioinformatics Database in Proteomics
Dr. Joel Rossier, CSO, DiagnoSwiss S.A., Switzerland |
| 14:45-15:10 |
Title: The Use of Support Vector Machine (SVM) Technology to Develop Molecular Diagnostic Tests
Dr. Stephen D. Barnhill, Chairman and Chief Executive Officer, Health Discovery Corporation, USA |
| 15:10-15:25 |
Coffee Break |
| 15:25-15:50 |
Title: A Chemical Proteomics Approach to Phosphatidylinositol 3-Kinase Signaling in Macrophages
Dr. Christian Pasquali, Professor, Geneva Research Center, Merck Serono International S.A., Switzerland |
| 15:50-16:15 |
Title:
Computational Genetics: Toward Understanding Our Drugs and Diseases
Dr. Guochun Liao, Group Leader, Roche Pharmaceuticals, USA |
| 16:15-16:40 |
Speech Opportunity is Available |
| 16:40-17:05 |
Title: Nutrigenomic and Immunosenescence
Dr. Eugenio Mocchegiani, Immunology Centre, (Section: Nutrition, Immunity and Ageing). Res. Dept. Italian National Research Centres on Ageing (I.N.R.C.A), Italy |
| 17:05-17:30 |
Panel Discussion
3-5 topics will be proposed by Session Chair |
|
Oct.18, 2008
Saturday
13:30-17:30
|
Session 2:
Regenerative Medicine and Drug Discovery |
Session Chair: |
Dr. Christophe Labie, Head, Neurobiology Group, Sanofi-aventis, Inc., France |
Co-Chair: |
Call for Co-Host |
| 13:30-13:55 |
Title: Novel Polymeric Artificial Cells for Nanomedicine and Regenerative Medicine
Dr. Thomas Ming Swi Chang, Director, Artificial Cells & Organs Research Centre, McGill University, Canada |
| 13:55-14:20 |
Speech Opportunity is Available |
| 14:20-14:45 |
Title: Stem cells and Regenerative Medicine
Dr. Michele De Luca, Full Professor of Biochemistry and Director, Centre for Regenerative Medicine, Department of Biomedical Sciences, University of Modena and Reggio Emilia, Italy |
| 14:45-15:10 |
Speech Opportunity is Available |
| 15:10-15:25 |
Coffee Break |
| 15:25-15:50 |
Title: TBD
Dr. Christophe Labie, Head, Neurobiology Group, Sanofi-aventis, Inc., France |
| 15:50-16:15 |
Title: TBD
Dr. Masaaki Kitada, Professor, Department of Anatomy and Neurobiology, Kyoto University Graduate School of Medicine, Japan |
| 16:15-16:40 |
Speech Opportunity is Available |
| 16:40-17:05 |
Speech Opportunity is Available |
| 17:05-17:30 |
Panel Discussion
3-5 topics will be proposed by Session Chair |
|
Oct.18, 2008
Saturday
13:30-17:30
|
Session 3:
Molecular/Cell Biology and Drug Discovery |
Session Chair: |
Dr. Michael R. Briggs, Senior Director and Head of Cell & Molecular Biology, Vertex Pharmaceuticals, Inc., USA |
Co-Chair: |
Dr. Jingwen Liu, Principal Investigator, VA Palo Alto Health Care System, USA |
| 13:30-13:55 |
Title: Finding Novel Cancer Drugs that Address Unmet Medical Needs
Dr. Michael R. Briggs, Senior Director and Head of Cell & Molecular Biology, Vertex Pharmaceuticals, Inc., USA |
| 13:55-14:20 |
Speech Opportunity is Available |
| 14:20-14:45 |
Title: TBD
Dr. Huichuan Sun, Porfessor, Liver Cancer Institute of Fudan University, China |
| 14:45-15:10 |
Title: Peptide Inhibitors of Metastasis in Liver Cancer
Dr. Yinkun Liu, Deputy Director, Liver Cancer Institute of Fudan University, China |
| 15:10-15:25 |
Coffee Break |
| 15:25-15:50 |
Title: The Identifications of the Molecular Targets for Berberine Mediated Cholesterol Reduction in Plasma and in Liver
Dr. Jingwen Liu, Principal Investigator, VA Palo Alto Health Care System, USA |
| 15:50-16:15 |
Title: TBD
Dr. Ilho Ha, Director, BioScience Center Hanwha Chemical R&D Institute Hanwha Chemical Co., Korea |
| 16:15-16:40 |
Speech Opportunity is Available |
| 16:40-17:05 |
Title: Wisdom: Grid Computing Enabled Identification of Active Molecules against Targets Implicated in Malaria
Dr. Vincent Breton, Research Associate, CNRS-IN2P3 Laboratory, France |
| 17:05-17:30 |
Panel Discussion
3-5 topics will be proposed by Session Chair |
|
Oct.18, 2008
Saturday
13:30-17:30
|
Session 4:
Immunology and Drug Discovery |
Session Chair: |
Dr. Prakash Nagarkatti, Associate Dean for Basic Science, University of South Carolina School of Medicine, USA |
Co-Chair: |
Call for Co-Host |
| 13:30-13:55 |
Title: Synthesis and Assembly Of Human Papillomavirus Type 16 L 1 Virus-like Particles
Dr. Robin L. Thurmond, Project Leader, Johnson & Johnson Pharmaceutical Research, USA |
| 13:55-14:20 |
Speech Opportunity is Available! |
| 14:20-14:45 |
Speech Opportunity is Available! |
| 14:45-15:10 |
Title: The Interleukin-6 Inflammation Pathway from Cholesterol to Aging ¨C Role of Statins, Bisphosphonates and Plant Polyphenols in Aging and Age-related Diseases
Dr. Sota Omoigui, Director, Division of Inflammation and Pain Medicine, L.A Pain Clinic, USA |
| 15:10-15:25 |
Coffee Break |
| 15:25-15:50 |
Title: Use of Cannabinoids as Novel Anti-inflammatory Drugs through Potential Targeting of CB2 Receptors
Dr. Prakash Nagarkatti, Associate Dean for Basic Sciences, University of South Carolina School of Medicine, USA |
| 15:50-16:15 |
Title: Targeting the Cannabinoid System as a Novel Therapeutic Modality to Treat Cancers of the Immune System
Dr. Mitzi Nagarkatti, Deputy Director of Cancer, University of South Carolina, USA |
| 16:15-16:40 |
Title: Novel Aryl-thiazolidones and Their Complexes with Ruthenium: Endowed with Anti- trypanosoma Cruzi Activity
Dr. Ana Cristina Lima Leite, Professor and Director, Federal University of Pernambuco, Brazil |
| 16:40-17:05 |
Speech Opportunity is Available |
| 17:05-17:30 |
Title: Neural Mechanism Involved in Chagas Cardiomyooathy: From Neurogenic to Immunogenic Trophic Theories
Dr. Rafael Bonfante-Cabarcas, Director of Biomedical Science PhD Program, Department of Functional Science, School of Medicine, Universidad Cent occidental "Lisandro Alvarado", Venezuela |
| 17:30-17:55 |
Panel Discussion
3-5 topics will be proposed by Session Chair |
|
Oct.18, 2008
Saturday
13:30-17:30
|
Session 5:
Oncology and Drug Discovery |
Session Chair: |
Call for Host |
Co-Chair: |
Dr. M. Asif Chaudry, University Department of Surgery Royal Free & University College London, UK |
| 13:30-13:55 |
Title: Tumor-Selective Anticancer Drugs from Amphiphilic Organophosphazenes
Dr. Youn Soo Sohn, Distinguished Professor, Department of Chemistry, Division of Nano Science, Ewha Womans University, Korea |
| 13:55-14:20 |
Title: Fragment Based Drug Discovery Using Rational Design
Dr. Harren Jhoti, Chief Executive Officer, Astex Therapeutics, Cambridge, UK |
| 14:20-14:45 |
Title: TBD
Dr. M Asif Chaudry, University Department of Surgery Royal Free & University College London, UK |
| 14:45-15:10 |
Title: Membrane Transporters in Oncology Drug Discovery
Dr. Bal¨¢zs Sarkadi, Professor, Head of the Membrane Research Group, Hungarian Academy of Sciences, Hungary |
| 15:10-15:25 |
Coffee Break |
| 15:25-15:50 |
Title: TBD
Dr. Hwei-Ru Tsou, Principal Research Scientist, Wyeth Research, USA |
| 15:50-16:15 |
Title: Prodigiosin, a New Apoptotic Agent with Anticancer Properties
Dr. Ricardo P¨¦rez-Tom¨¢s, Professor, School of Medicine, University of Barcelona, Spain |
| 16:15-16:40 |
Title: Targeting Multidrug Resistant Cancer
Dr. Gergely Szak¨¢cs, Professor, Institute of Enzymology, Biological Research Center, Hungarian Academy of Sciences, Budapest, Hungary |
| 16:40-17:05 |
Title: The SV40 Large T Antigen-p53 Complexes Bind and Activate the Insulin-like Growth Factor-I Promoter Stimulating Cell Growth
Dr. Michele Carbone, Professor and Chairman, Department of Pathology, John A. Burns School of Medicine; Director Thoracic Oncology Program, Cancer Research Center, University of Hawaii, USA |
| 17:05-17:30 |
Speech Opportunity is Available |
| 17:30-17:55 |
Title: PET Microdosing in Anticancer Drug Development
Dr. Kirsten Bouchelouche, Place City Odense University Hospital, Denmark |
| 17:55-18:15 |
Panel Discussion
3-5 topics will be proposed by Session Chair |
|
Oct.18, 2008
Saturday
13:30-17:30
|
Session 6:
Microbiology, Virology and Drug Discovery |
Session Chair: |
Call for Host |
Co-Chair: |
Call for Co-Host |
| 13:30-13:55 |
Title: Discovering Enteric Dialysis ¨C The Gut Based Uremia Therapy for Chronic Kidney Failure Applications
Dr. N. Ranganthan, Interim CEO, Kibow Biotech, USA |
| 13:55-14:20 |
Title: TBD
Dr. Thomas Baumert, Director, University Louis Pasteur, France |
| 14:20-14:45 |
Title: Structure Guided Design, Synthesis and Characterization of Inhibitors of the Bacterial enoyl-ACP Reductase FabI
Dr. Judd Berman, CSO, Dalton Medicinal Chemistry, Inc., USA |
| 14:45-15:10 |
Title: TBD
Dr. Orig¨¨ne Nyanguile, Principal Scientist, Tibotec BVBA, Belgium |
| 15:10-15:25 |
Coffee Break |
| 15:25-15:50 |
Title: TBD
Dr. Michael Bukrinsky, Professor and Vice Chair, The George Washington University, USA |
| 15:50-16:15 |
Speech Opportunity is Available! |
| 16:15-16:40 |
Title: TBD
Dr. Ming Q Wei, Editorial Board, University of Queensland, Australia |
| 16:40-17:05 |
Title: TBD
Dr. Mia Levite, Senior Scientist/Lecturer, The Weizmann Institute of Science, Israel |
| 17:05-17:30 |
Panel Discussion
3-5 topics will be proposed by Session Chair |
|
Oct.18, 2008
Saturday
13:30-17:30
|
Session 7:
Neurology and Drug Discovery |
Session Chair: |
Call for Host |
Co-Chair: |
Call for Co-Host |
| 13:30-13:55 |
Title: TBD
Dr. Michael A. Palladino, Jr., Senior Vice President, Chief Technology Officer and Scientific Co-founder, Neuropharm, Inc., USA |
| 13:55-14:20 |
Title: Copper Homeostasis and Neurodegenerative Disorders (Alzheimer's, Prion, and Parkinson's Diseases): What can be Learned by Studies on Cu(II)-peptide Complexes
Dr. Gianni Valensin, Professor, Director of the NMR Centre of the University of Siena, Italy |
| 14:20-14:45 |
Title: TCA Cycle May Play an Important Role for Protection Against Epileptic Seizures
Dr. Hiro-aki Yamamoto, Associate Professor, University of Tsukuba, Japan |
| 14:45-15:10 |
Title: The Neurobiological Bases of AED Resistance
Dr. Lazarowski Alberto, Clinical Biochemistry Department,
PlaceType School PlaceName of Pharmacy and Biochemistry, PlaceType University of PlaceName Buenos Aires (UBA), Argentina
|
| 15:10-15:25 |
Coffee Break |
| 15:25-15:50 |
Title: TBD
Dr. Sabina Janciauskiene, Lund Universit, University Hospital, Sweden |
| 15:50-16:15 |
Title: Mechanism-based Development of Memantine as A Therapeutic Agent in Treating Alzheimer's Disease and other Neurologic Disorders
Dr. HS Vincent Chen, Assistant Professor, University of California, USA |
| 16:15-16:40 |
Title: Serotonin 5-HT 1A Receptors : How New Mechanisms are Driving Innovation and Drug Discovery
Dr. Adrian Newman-Tancredi, Director, Neurobiology 2 Division, Institut de Recherche Pierre Fabre, France |
| 16:40-17:05 |
Title: TBD
Dr. Jorge Ju¨¢rez, Professor, Universidad de Guadalajara, M¨¦xico |
| 17:05-17:30 |
Panel Discussion
3-5 topics will be proposed by Session Chair |
|
Oct.18, 2008
Saturday
13:30-17:30
|
Session 8:
Hepatology and Drug Discovery |
Session Chair: |
Call for Host |
Co-Chair: |
Call for Co-Host |
| 13:30-13:55 |
Call for Keynote Speaker |
| 13:55-14:20 |
Title: Chemoembolizattion of Hepatic Neoplasm with Drug-eluting Microspheres
Dr. T. Gregory Walker, Section of Cardiovascular Imaging and Intervention, Massachusetts General Hospital, USA |
| 14:20-14:45 |
Speech Opportunity is Available |
| 14:45-15:10 |
Title: An Old Drug for a New Therapeutic Frontier: ACE Inhibitors in the Battle against Liver Fibrosis
Dr. Igino Rigato, Senior Investigator, AREA Science Park and University Hospital of Trieste, Italy |
| 15:10-15:25 |
Coffee Break |
| 15:25-15:50 |
Title: Drug Structure- Hepatic Pharmacokinetic Relationships in Normal and Diseased Livers
Dr. Michael S Roberts, University of Queensland, Australia |
| 15:50-16:15 |
Speech Opportunity is Available |
| 16:15-16:40 |
Speech Opportunity is Available |
| 16:40-17:05 |
Title: The 3D Cell Models and Supporting Technologies for Hepatotoxicity Testing of Drugs
Dr. Hanry Yu, Associate Professor, National University of Singapore, Singapore |
| 17:05-17:30 |
Panel Discussion
3-5 topics will be proposed by Session Chair |
|
Oct.18, 2008
Saturday
13:30-17:30
|
Session 9:
Endocrinology and Drug Discovery
|
Session Chair: |
Call for Host |
Co-Chair: |
Call for Co-Host |
| 13:30-13:55 |
Call for Keynote Speaker |
| 13:55-14:20 |
Title: TBD in Field of Diabetes or Kinase Inhibitor
Dr. Tang Peng Cho, Chief Scientific Officer, Shanghai Hengrui Pharmaceuticals, China |
| 14:20-14:45 |
Title: Progress and Limitation of the Andidiabetic Drug Treatment
Dr. Guntram Schernthaner, Professor andHead, Rudolfstiftung Hospital-Vienna, Austria |
| 14:45-15:10 |
Speech Opportunity is Available |
| 15:10-15:25 |
Coffee Break |
| 15:25-15:50 |
Speech Opportunity is Available |
| 15:50-16:15 |
Title: Investigating Effects of Anesthetics on Bbeta Amyloid Peptide Accumulation and Aggregation, the Key Pathogenic Event in Alzheimer Disease
Dr. Vincenzo Fodale, Aggregate Professor, University of Messina, Italy |
| 16:15-16:40 |
Speech Opportunity is Available |
| 16:40-17:05 |
Speech Opportunity is Available |
| 17:05-17:30 |
Panel Discussion
3-5 topics will be proposed by Session Chair |
|
Oct.18, 2008
Saturday
13:30-17:30
|
Session 10:
Pharmacology, Toxicology and Pathology in Drug Discovery
|
Session Chair: |
Dr. Tian Yang, Research Leader, Roche Pharmaceuticals, USA |
| | | |